Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development expenses	$ 5,161,315	$ 1,413,057
General and administrative expenses	3,317,907	1,636,216
Total operating expenses	8,479,222	3,049,273
Loss from operations	(8,479,222)	(3,049,273)
Other income:
Interest income	5,700	655
Net loss	(8,473,522)	(3,048,618)
Comprehensive loss	$ (8,473,522)	$ (3,048,618)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.32)	$ (0.14)
Net loss per share, diluted (in dollars per share)	$ (0.32)	$ (0.14)
Weighted average common shares outstanding, basic (in shares)	26,161,156	22,263,838
Weighted average common shares outstanding, diluted (in shares)	26,161,156	22,263,838